Cite
Veenstra VL, Damhofer H, Waasdorp C, et al. ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. Oncogenesis. 2018;7(11):87doi: 10.1038/s41389-018-0096-9.
Veenstra, V. L., Damhofer, H., Waasdorp, C., van Rijssen, L. B., van de Vijver, M. J., Dijk, F., Wilmink, H. W., Besselink, M. G., Busch, O. R., Chang, D. K., Bailey, P. J., Biankin, A. V., Kocher, H. M., Medema, J. P., Li, J. S., Jiang, R., Pierce, D. W., van Laarhoven, H. W. M., & Bijlsma, M. F. (2018). ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. Oncogenesis, 7(11), 87. https://doi.org/10.1038/s41389-018-0096-9
Veenstra, V L, et al. "ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy." Oncogenesis vol. 7,11 (2018): 87. doi: https://doi.org/10.1038/s41389-018-0096-9
Veenstra VL, Damhofer H, Waasdorp C, van Rijssen LB, van de Vijver MJ, Dijk F, Wilmink HW, Besselink MG, Busch OR, Chang DK, Bailey PJ, Biankin AV, Kocher HM, Medema JP, Li JS, Jiang R, Pierce DW, van Laarhoven HWM, Bijlsma MF. ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. Oncogenesis. 2018 Nov 16;7(11):87. doi: 10.1038/s41389-018-0096-9. PMID: 30442938; PMCID: PMC6237826.
Copy
Download .nbib